SCHEMBL3408685

SCHEMBL3408685

CC(C)(C)[Si](C)(C)OCc1ccccc1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.53
BACE1 P56817 1/20 0.44
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
RIPK1 Q13546 1/20 0.40
TAAR1 Q96RJ0 3/20 0.38
ALDH1A1 P00352 4/20 0.37
CARM1 Q86X55 1/20 0.37
PRMT6 Q96LA8 1/20 0.37
PARP10 Q53GL7 1/20 0.36
MAPT P10636 3/20 0.36
RAB9A P51151 3/20 0.36
NPC1 O15118 2/20 0.36
HTT P42858 2/20 0.35
KMT2A Q03164 2/20 0.35
TSHR P16473 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14992909 0.83 BACE1 (0.38) IDO1BACE1RIPK1MAPT
SCHEMBL30271106 0.83 TAAR1 (0.43) IDO1BACE1CA12CA9RIPK1
SCHEMBL6347925 0.83 TAAR1 (0.43) IDO1BACE1CA12CA9RIPK1
SCHEMBL7922813 0.82 BACE1 (0.44) IDO1BACE1MAPTHTT
SCHEMBL30703393 0.81 BACE1 (0.39) IDO1BACE1RIPK1TAAR1CARM1
SCHEMBL9204132 0.81 IDO1 (0.55) IDO1CA12CA9TAAR1ALDH1A1
SCHEMBL7134633 0.81 BACE1 (0.43) IDO1BACE1RIPK1TAAR1MAPT
SCHEMBL16010314 0.80 BACE1 (0.38) IDO1BACE1MAPTHTTSMN1; SMN2
SCHEMBL9566221 0.80 TAAR1 (0.41) IDO1BACE1CA12CA9RIPK1
SCHEMBL30667522 0.80 TAAR1 (0.41) IDO1BACE1CA12CA9RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435087-B2 Modulators of DCN-1 and methods of use thereof CELLARITY, INC. (US) 2025-10-07 US disclosed
US-20250163058-A1 MODULATORS OF DCN-1 AND METHODS OF USE THEREOF THAMES PHARMA PARTNERS 2025-05-22 US disclosed
WO-2025096981-A1 MODULATORS OF DCN-1 AND METHODS OF USE THEREOF CELLARITY, INC. (US) 2025-05-08 WO disclosed
US-20220259226-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2022-08-18 US disclosed
US-20210292339-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2021-09-23 US disclosed
US-20200255451-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2020-08-13 US disclosed
US-20190055264-A1 Macrocyclic MCL-1 inhibitors and methods of use AbbVie Deutschland GmbH & Co. KG (DE) 2019-02-21 US disclosed
EP-2262805-B1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-22 EP disclosed
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (US) 2013-05-16 US disclosed
US-8338451-B2 Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2012-12-25 US disclosed
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed
EP-2262805-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2010-12-22 EP disclosed
WO-2009144395-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-12-03 WO disclosed
EP-1308436-B1 CALCIUM RECEPTOR ANTAGONISTS JAPAN TOBACCO INC (JP) 2008-10-15 EP disclosed
US-7211685-B2 Calcium receptor antagonists JAPAN TOBACCO INC. (JP) 2007-05-01 US disclosed
US-7211685-B2 Calcium receptor antagonists JAPAN TOBACCO INC. (JP) 2007-05-01 US disclosed
US-6916956-B2 Calcium receptor antagonist JAPAN TOBACCO, INC. (JP) 2005-07-12 US disclosed
US-20050107448-A1 Calcium receptor antagonists JAPAN TABACCO INC. 2005-05-19 US disclosed
US-20040006130-A1 Calcium receptor antagonist JAPAN TOBACCO INC (JP) 2004-01-08 US disclosed
EP-1308436-A1 CALCIUM RECEPTOR ANTAGONISTS JAPAN TOBACCO INC. (JP) 2003-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN IDO1 1097/4885BACE1 3042/4885CA12 1714/4885
US-20210292339-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 IDO1 3626/4885BACE1 3087/4885CA12 4298/4885
US-20190055264-A1 Macrocyclic MCL-1 inhibitors and methods of use MCL1, BCL2A1, BCL2L10 IDO1 3626/4885BACE1 3087/4885CA12 4298/4885
US-20200255451-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 IDO1 3626/4885BACE1 3087/4885CA12 4298/4885
US-20050107448-A1 Calcium receptor antagonists CASR, CALCR, CALCRL IDO1 3897/4885BACE1 1170/4885CA12 1898/4885
US-20250163058-A1 MODULATORS OF DCN-1 AND METHODS OF USE THEREOF DCUN1D1, DCUN1D2, DCUN1D4 IDO1 3378/4885BACE1 4847/4885CA12 4543/4885
US-20040006130-A1 Calcium receptor antagonist CALCRL, CASR, CALCR IDO1 3541/4885BACE1 1227/4885CA12 2096/4885
US-20220259226-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 IDO1 3626/4885BACE1 3087/4885CA12 4298/4885
US-12435087-B2 Modulators of DCN-1 and methods of use thereof DCUN1D1, DCUN1D2, DCUN1D4 IDO1 3378/4885BACE1 4847/4885CA12 4543/4885
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN IDO1 1097/4885BACE1 3042/4885CA12 1714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.